Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Lx1032
2. Xermelo
1. 1033805-22-9
2. Lx1606
3. Lx 1606
4. Xermelo
5. (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate
6. Lx-1606
7. Telotristat Ethyl [usan]
8. Lx 1032
9. Lx1032
10. Lx-1032
11. Ethyl (2s)-2-amino-3-[4-[2-amino-6-[(1r)-1-[4-chloro-2-(3-methylpyrazol-1-yl)phenyl]-2,2,2-trifluoroethoxy]pyrimidin-4-yl]phenyl]propanoate
12. 8g388563m7
13. Telotristat Ethyl (usan)
14. Lx-1606 Hippurate
15. Telotristat Etiprate (lx 1606 Hippurate)
16. Telotristat-ethyl
17. Unii-8g388563m7
18. Xermelo (tn)
19. Schembl610588
20. Telotristat Ethyl [mi]
21. Gtpl9490
22. Chembl2105695
23. Ex-a322
24. Bdbm445704
25. Dtxsid001102271
26. Telotristat Ethyl [who-dd]
27. Amy38688
28. Hy-13055a
29. Lx1606lx1606
30. Mfcd18251583
31. Zinc43205655
32. Bcp9000866
33. Db12095
34. Us10683309, Example Lx1606
35. Ncgc00390241-01
36. Ncgc00390241-07
37. As-35061
38. D09974
39. J-524318
40. Q27270371
41. Ethyl 4-(2-amino-6-((1r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pryrimidin-4-yl)-l-phenylalaninate
42. L-phenylalanine, 4-(2-amino-6-((1r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-4-pryrimidinyl)-, Ethyl Ester
Molecular Weight | 575.0 g/mol |
---|---|
Molecular Formula | C27H26ClF3N6O3 |
XLogP3 | 5.1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 10 |
Exact Mass | 574.1707009 g/mol |
Monoisotopic Mass | 574.1707009 g/mol |
Topological Polar Surface Area | 131 Ų |
Heavy Atom Count | 40 |
Formal Charge | 0 |
Complexity | 821 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 1 | |
---|---|
Drug Name | XERMELO |
Active Ingredient | TELOTRISTAT ETIPRATE |
Company | LEXICON PHARMS INC (Application Number: N208794. Patents: 7553840, 7709493, 7968559, 8193204, 8653094) |
As a serotonin synthesis inhibitor, telotristat etiprate, has the potential to reduce serotonin levels and address the key elements of carcinoid syndrome.
Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy.
Activity is mainly in the gastrointestinal tract, with minimal effects reported on the brain and cardiovascular system, accompanied by an excellent safety profile. In normal mice, telotristat etiprate (administered once daily for 4 days at doses of 15300 mg/kg/day) was found to reduce serotonin levels throughout the gastrointestinal tract. These reductions occurred in a dose dependent fashion with maximal effects observed with doses of telotristat etiprate 150 mg/kg. No significant change in brain serotonin or 5-hydroxyindoleacetic acid (5-HIAA, a serotonin metabolite) was observed. Similar findings were seen in Sprague-Dawley rats. Gastrointestinal motility studies were conducted in rats using the charcoal meal test. There was a significant dose-related delay in both gastrointestinal transit and gastric emptying, associated with a reduction in blood serotonin levels and proximal colon serotonin. A quantitative whole-body autoradiography study was conducted to assess the absorption, distribution and excretion of radioactivity in rats following a single oral dose of telotristat etiprate labeled with carbon 14. Rats were administered either 30 mg/kg or 100 mg/kg of the compound. The distribution of radioactivity was limited to tissues of the hepatic and renal system and the contents of the GI tract. There was no measurable radioactivity in the brain at any dose tested.
A16A
Absorption
Low systemic absorption. Tmax of 24 h, supporting the 8-hourly administration
Route of Elimination
Telotristat ethyl is mainly excreted in feces.
Clearance
Not available
Metabolized by the liver.
412 h
Telotristat etiprate is an ethyl ester prodrug which is hydrolyzed to its active moiety LP-778902 both in vivo and in vitro. Systemic exposure of telotristat etiprate is relatively low, as the hydrolysis to the active moiety is rapid. LP-778902 is a potent inhibitor of TPH with an in vivo IC50 of 0.028 M. While existing treatments for carcinoid syndrome work to reduce the release of serotonin outside tumor cells, telotristat etiprate works at the source to reduce serotonin production within the tumor cells. By specifically inhibiting serotonin production, telotristat etiprate seeks to control this important driver of carcinoid syndrome and, in turn, provide patients with more control over their disease.
Details:
Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Lead Product(s): Telotristat Ethyl
Therapeutic Area: Gastroenterology Brand Name: Xermelo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
Lead Product(s) : Telotristat Ethyl
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TerSera® Presents Patient-Reported Clinical and Productivity Outcomes Associated with Xermelo® (...
Details : Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Brand Name : Xermelo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 09, 2021
Details:
With this agreement including the repayment of Lexicon’s secured loan concurrent with the closing of its sale of XERMELO®, Lexicon will have reduced the principal amount of its outstanding debt, supporting advancement of its LX9211 neuropathic pain program and other trials.
Lead Product(s): Telotristat Ethyl
Therapeutic Area: Gastroenterology Brand Name: Xermelo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Undisclosed
Deal Size: $62.5 million Upfront Cash: $41.0 million
Deal Type: Agreement September 23, 2020
Lead Product(s) : Telotristat Ethyl
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : $62.5 million
Deal Type : Agreement
Details : With this agreement including the repayment of Lexicon’s secured loan concurrent with the closing of its sale of XERMELO®, Lexicon will have reduced the principal amount of its outstanding debt, supporting advancement of its LX9211 neuropathic pain pr...
Brand Name : Xermelo
Molecule Type : Small molecule
Upfront Cash : $41.0 million
September 23, 2020
Details:
As part of the transaction, TerSera has agreed to assume the currently ongoing TELE-ABC Phase 2 clinical study of XERMELO in biliary tract cancer patients.
Lead Product(s): Telotristat Ethyl
Therapeutic Area: Oncology Brand Name: Xermelo
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: TerSera
Deal Size: $224.0 million Upfront Cash: $159.0 million
Deal Type: Agreement July 30, 2020
Lead Product(s) : Telotristat Ethyl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : TerSera
Deal Size : $224.0 million
Deal Type : Agreement
Lexicon Pharmaceuticals Enters Into Agreement With Tersera Therapeutics For The Sale Of Xermelo
Details : As part of the transaction, TerSera has agreed to assume the currently ongoing TELE-ABC Phase 2 clinical study of XERMELO in biliary tract cancer patients.
Brand Name : Xermelo
Molecule Type : Small molecule
Upfront Cash : $159.0 million
July 30, 2020
Details:
Lexicon Pharmaceutical to present four posters highlighting XERMELO at the virtual Cholangiocarcinoma Foundation Annual Conference. XERMELO targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within metastatic neuroendocrine tumor cells.
Lead Product(s): Telotristat Ethyl
Therapeutic Area: Oncology Brand Name: Xermelo
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Lead Product(s) : Telotristat Ethyl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Lexicon Pharmaceutical to present four posters highlighting XERMELO at the virtual Cholangiocarcinoma Foundation Annual Conference. XERMELO targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within metastatic neuroend...
Brand Name : Xermelo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 20, 2020
Details:
Additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines were presented at the ASCO 2020 annual meeting.
Lead Product(s): Telotristat Ethyl
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Lead Product(s) : Telotristat Ethyl
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lexicon Pharmaceuticals Shares Preclinical Efficacy Data on Telotristat Ethyl’s Antiproliferativ...
Details : Additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines were presented at the ASCO 2020 annual meeting.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 13, 2020
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
ABOUT THIS PAGE
A Telotristat Ethyl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Telotristat Ethyl, including repackagers and relabelers. The FDA regulates Telotristat Ethyl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Telotristat Ethyl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Telotristat Ethyl supplier is an individual or a company that provides Telotristat Ethyl active pharmaceutical ingredient (API) or Telotristat Ethyl finished formulations upon request. The Telotristat Ethyl suppliers may include Telotristat Ethyl API manufacturers, exporters, distributors and traders.
Telotristat Ethyl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Telotristat Ethyl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Telotristat Ethyl GMP manufacturer or Telotristat Ethyl GMP API supplier for your needs.
A Telotristat Ethyl CoA (Certificate of Analysis) is a formal document that attests to Telotristat Ethyl's compliance with Telotristat Ethyl specifications and serves as a tool for batch-level quality control.
Telotristat Ethyl CoA mostly includes findings from lab analyses of a specific batch. For each Telotristat Ethyl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Telotristat Ethyl may be tested according to a variety of international standards, such as European Pharmacopoeia (Telotristat Ethyl EP), Telotristat Ethyl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Telotristat Ethyl USP).
LOOKING FOR A SUPPLIER?